SCHEMBL18575482

SCHEMBL18575482

Nc1ccc(Br)c2c1NCCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
MPI P34949 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PARP1 P09874 4/20 0.33
HTR2C P28335 1/20 0.33
PRKD1 Q15139 1/20 0.32
PARP10 Q53GL7 1/20 0.32
PARP11 Q9NR21 1/20 0.32
AXL P30530 1/20 0.31
BCHE P06276 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31038425 1.00 KDM4E (0.35) KDM4EMEN1ALDH1A1TP53GAA
SCHEMBL30675774 0.89 PARP10 (0.41) MEN1ALDH1A1MAPTKMT2APARP1
SCHEMBL24317405 0.89 PARP10 (0.41) MEN1ALDH1A1MAPTKMT2APARP1
SCHEMBL31731343 0.84 ALDH1A1 (0.39) KDM4EMEN1ALDH1A1TP53GAA
SCHEMBL15690264 0.79 UHRF1 (0.37) KDM4EMEN1ALDH1A1TP53GAA
SCHEMBL11901340 0.78 PARP1 (0.44) KDM4EMEN1ALDH1A1TP53GAA
SCHEMBL10911937 0.78 ALDH1A1 (0.42) KDM4EMEN1ALDH1A1TP53GAA
SCHEMBL11901695 0.73 PARP1 (0.43) KDM4EMEN1ALDH1A1TP53GAA
SCHEMBL5328612 0.73 PARP1 (0.39) KDM4EMEN1ALDH1A1TP53GAA
SCHEMBL844986 0.71 IL1RN (0.37) MEN1ALDH1A1MAPTHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059196-A1 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-02-20 US disclosed
WO-2024259303-A1 COMPOUNDS AND COMPOSITIONS AS CEREBLON LIGANDS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2024-12-19 WO disclosed
EP-4458819-A1 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-11-06 EP disclosed
WO-2023125877-A1 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2023-07-06 WO disclosed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
EP-2917217-B1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA S A (PL) 2017-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059196-A1 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF WEE1, CYP51A1, WEE2 KDM4E 2363/4885MEN1 257/4885ALDH1A1 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.